Indinavir/ritonavir remains an important component of HAART for the treatment of HIV/AIDS, particularly in resource-limited settings

• Main Authors: Tim R. Cressey, Plipat Nottasorn, Federica Fregonese, Kulkanya Chokephaibulkit
• Format: Journal
• Published: 2018
• Subjects: Pharmacology, Toxicology and Pharmaceutics
• Online Access: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=34548273143&origin=inward; http://cmuir.cmu.ac.th/jspui/handle/6653943832/61374
• Institution: Chiang Mai University

For over a decade, indinavir has been approved for the treatment of HIV/ AIDS; however, following the introduction of new protease inhibitors (PIs) with improved safety and pharmacologic profiles, its use in developed countries has become almost obsolete. In contrast, in resource-limited settings wh...